Loading...
NPI 1720063688 · Camp Hill, PA · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Steven Truong is a ophthalmology physician provider located in Camp Hill, Pennsylvania. This profile covers 17 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Steven Truong |
| Address | 220 Grandview Ave |
| City | Camp Hill |
| State | PA |
| ZIP | 17011 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | December 13, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.7M |
| Medicaid | $11.5K |
Medicare is the primary revenue source for this provider: reported Medicare revenue is $2.7M compared with Medicaid revenue of $11.5K, so the practice’s payer mix is overwhelmingly Medicare-driven and effectively single-payer in scale. This gap indicates that business performance and risk are tied chiefly to Medicare reimbursement and utilization patterns rather than to Medicaid volumes.
Revenue concentration on a few high-cost drugs is acute: the precomputed top 3 Medicare codes account for 84.5% of this provider’s Medicare revenue, driven by J0178 (29.7%), J2778 (28.6%), and J2777 (26.2%). Those three codes are all injectable intravitreal drugs, so the provider’s Medicare revenue depends heavily on anti-VEGF/retinal biologic therapies rather than a broad mix of services.
Clinical/service-line implication: the dominant CPT/HCPCS mix (J0178, J2778, J2777 plus frequent use of 67028 and retinal imaging 92134) is consistent with a retina-focused ophthalmology practice that performs repeated intravitreal injections and routine retinal imaging. Presence of 67028 (intravitreal injection) and high-volume imaging services supports an operating model built around recurrent in-office procedures and longitudinal monitoring of retinal disease.
Operational footprint and visit volume: claim counts show high throughput for injection therapies (J2777: 24.4K claims; J2778: 4.3K claims; J0178: 1.2K claims) together with substantial E/M activity (99213: 934 claims). The provider’s volume profile—large numbers of injection claims combined with frequent low‑level E/M visits—is typical of practices that manage chronic retinal conditions with regular injection visits and brief follow-up encounters.
Competitive standing on key Medicare codes is mixed: the provider ranks strongly on ranibizumab (J2778 rank #61 of 1208, 95th percentile), meaning a top-tier national position for that drug, while aflibercept (J0178 rank #1119 of 3204, 65th percentile) and faricimab (J2777 rank #406 of 2039, 80th percentile) are in the typical-to-above-typical range. Non-drug services also show above-typical national standing—67028 ranks #313 of 4255 (93th percentile) and 92134 ranks #826 of 26868 (97th percentile)—indicating particularly strong throughput on intravitreal procedure and retinal imaging relative to peers.
Medicaid activity is minimal and concentrated: the precomputed top 3 Medicaid codes account for 100.0% of Medicaid revenue, with 67028 ($7K, 61.4% of Medicaid revenue) and 92134 ($4.4K, 38.6% of Medicaid revenue) explicitly on file. In-state ranks for those Medicaid services are modest (67028 at the 39th percentile and 92134 at the 52th percentile), so the provider is not a high-impact Medicaid competitor within Pennsylvania despite performing the same injection and imaging services seen in Medicare.
Statistical outliers and lower-volume signals: the provider posts an "extreme outlier" national label on 99213 (98th percentile, far above typical national volume), indicating unusually high office-visit billing volume for that E/M level relative to peers. Conversely, usage of some drug codes is comparatively low nationally (for example J9035 ranks in the 1th percentile and J7312 in the 12th percentile), which suggests the practice selectively uses particular intravitreal agents and implants rather than a broad drug mix.
Tenure and overall profile: the NPI was enumerated on 2005-12-13 (≈21 years), reflecting long-standing participation in Medicare and Medicaid networks. Taken together, the data describe a long-tenured, retina-focused ophthalmology provider with high Medicare dependence, concentrated anti‑VEGF/drug revenue, strong national standing on select retinal injection and imaging services, and a very limited Medicaid footprint.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,170 | $690 | $801.5K |
| J2778 | Injection, ranibizumab, 0.1 mg | 4,270 | $180 | $772.9K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 24,420 | $30 | $708.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,170 | $80 | $177.5K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,250 | $30 | $65.2K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 930 | $60 | $58.8K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 300 | $90 | $25.6K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 150 | $150 | $22.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 250 | $90 | $21.7K |
| J7999 | Compounded drug, not otherwise classified | 240 | $60 | $15.4K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
17 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 59 | 140 | 830 | $690 | $865.1K |
| J2778 | 17 | 70 | 1,030 | $190 | $417.1K |
| J2777 | 14 | 100 | 7,950 | $30 | $360.2K |
| 67028 | 24 | 180 | 600 | $90 | $87.5K |
| J7312 | 14 | 10 | 280 | $160 | $50.7K |
| J7999 | 27 | 110 | 100 | $120 | $33.3K |
| 92014 | 428 | 1,570 | 130 | $80 | $21K |
| 99214 | 5,443 | 23,230 | 100 | $80 | $14.5K |
| 92012 | 487 | 930 | 80 | $60 | $14K |
| 92235 | 21 | 70 | 40 | $100 | $10K |
Showing 1–10 of 17
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 150 | $50 | $7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 300 | $20 | $4.4K |
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 61 | 100 | 330 | $70 | $85.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 89 | 180 | 290 | $20 | $24.8K |
Other providers in the same ZIP code as Steven Truong, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Medstaffers, LLC | PA | Home Health Agency | $0 | $15.1M |
| Penn State Health Holy Spirit Medical Center | PA | General Acute Care Hospital | $0 | $10.2M |
| Penn State Health Life Lion, LLC | PA | Ambulance | $2.4M | $6.9M |
| Shadai Healthcare Services LLC | PA | Home Health Agency | $0 | $9.2M |
| Paul Baker | PA | Ophthalmology Physician | $2.4M | $3.3K |
| Michael Banach | PA | Ophthalmology Physician | $2.1M | $5.1K |
| Tahsin Khundkar | PA | Ophthalmology Physician | $1.5M | $0 |
| Marissa Wedel | PA | Ophthalmology Physician | $1.4M | $26.3K |
| Rajesh Dave | PA | Cardiovascular Disease Physician | $934K | $0 |
| West Shore Endoscopy Center LLC | PA | Ambulatory Surgical Clinic/Center | $770.4K | $66.2K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.